| Literature DB >> 32463809 |
Amy V Dora, Alexander Winnett, Lauren P Jatt, Kusha Davar, Mika Watanabe, Linda Sohn, Hannah S Kern, Christopher J Graber, Matthew B Goetz.
Abstract
On March 28, 2020, two residents of a long-term care skilled nursing facility (SNF) at the Veterans Affairs Greater Los Angeles Healthcare System (VAGLAHS) had positive test results for SARS-CoV-2, the cause of coronavirus disease 2019 (COVID-19), by reverse transcription-polymerase chain reaction (RT-PCR) testing of nasopharyngeal specimens collected on March 26 and March 27. During March 29-April 23, all SNF residents, regardless of symptoms, underwent serial (approximately weekly) nasopharyngeal SARS-CoV-2 RT-PCR testing, and positive results were communicated to the county health department. All SNF clinical and nonclinical staff members were also screened for SARS-CoV-2 by RT-PCR during March 29-April 10. Nineteen of 99 (19%) residents and eight of 136 (6%) staff members had positive test results for SARS-CoV-2 during March 28-April 10; no further resident cases were identified on subsequent testing on April 13, April 22, and April 23. Fourteen of the 19 residents with COVID-19 were asymptomatic at the time of testing. Among these residents, eight developed symptoms 1-5 days after specimen collection and were later classified as presymptomatic; one of these patients died. This report describes an outbreak of COVID-19 in an SNF, with case identification accomplished by implementing several rounds of RT-PCR testing, permitting rapid isolation of both symptomatic and asymptomatic residents with COVID-19. The outbreak was successfully contained following implementation of this strategy.Entities:
Mesh:
Year: 2020 PMID: 32463809 PMCID: PMC7269604 DOI: 10.15585/mmwr.mm6921e1
Source DB: PubMed Journal: MMWR Morb Mortal Wkly Rep ISSN: 0149-2195 Impact factor: 17.586
Characteristics of long-term care skilled nursing facility residents with positive test results for SARS-CoV-2 (N = 19) — Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, 2020
| Characteristic | No. (%) | |||
|---|---|---|---|---|
| Asymptomatic* (n = 6) | Presymptomatic* (n = 8) | Symptomatic* (n = 5) | All (N = 19) | |
|
| ||||
|
| 75 (72–75) | 67 (66–84.5) | 84 (70–85) | 75 (66–85) |
|
| 6 (100) | 8 (100) | 5 (100) | 19 (100) |
|
| ||||
| Asian | — | — | — | — |
| Black or African American | 2 (33) | 4 (50) | 2 (40) | 8 (42) |
| Native Hawaiian or Pacific Islander | — | 1 (13) | — | 1 (5) |
| White | 3 (50) | 3 (38) | 2 (40) | 8 (42) |
| Unknown | 1 (17) | — | 1 (20) | 2 (11) |
| Hispanic | — | — | — | — |
|
| ||||
| Hypertension | 5 (83) | 5 (63) | 3 (60) | 13 (68) |
| Cardiovascular disease | 3 (50) | 4 (50) | 5 (100) | 12 (63) |
| Diabetes | 4 (67) | 5 (63) | 2 (40) | 11 (58) |
| Body mass index >30 kg/m2 | 3 (50) | 2 (25) | 2 (40) | 7 (37) |
| Chronic kidney disease (stage 4 or above) | — | 2 (25) | 1 (20) | 3 (16) |
| Chronic obstructive pulmonary disease | 1 (17) | 1 (13) | 2 (40) | 4 (21) |
|
| ||||
|
| — | 6 (75) | 5 (100) | 11 (58) |
| Fever | — | 6 (75) | 5 (100) | 11 (58) |
| Myalgia | — | — | 1 (20) | 1 (5) |
| Headache | — | 1 (13) | 1 (20) | 2 (11) |
|
| — | 4 (38) | 5 (100) | 9 (47) |
| Cough | — | 2 (25) | 5 (100) | 7 (37) |
| Dyspnea | — | 2 (25) | 1 (20) | 3 (16) |
|
| — | 5 (63) | 1 (20) | 6 (32) |
| Nausea | — | 1 (13) | — | 1 (5) |
| Emesis | — | 1 (13) | — | 1 (5) |
| Diarrhea | — | 2 (25) | — | 2 (11) |
| Poor appetite | — | 3 (38) | 1 (20) | 4 (21) |
|
| ||||
| WBC (x 1,000/ | 4.32 (3.67–5.91) [5] | 4.35 (3.93–6.10) [8] | 6.24 (6.09–7.08) [5] | 5.32 (3.94–6.20) [18] |
| Lymphocytes (%) | 31.5 (26.4–32.7) [5] | 22.0 (17.5–25.9) [8] | 16.7 (11.4–16.9) [5] | 22.0 (17.0–30.3) [18] |
| Lymphocytes (x 1,000/ | 1,200 (1,140–1,200) [5] | 960 (775–1,105) [8] | 880 (770–1,200) [5] | 1,025 (835–1,200) [18] |
| Creatinine (mg/dL) | 1.00 (0.89–1.05) [4] | 1.01 (0.82–1.07) [8] | 2.84 (1.99–3.23) [5] | 1.04 (0.88–1.41) [17] |
| AST (U/L) | 19 (17–21) [3] | 24 (20–29) [5] | 31 (NA) [1] | 22 (19–29) [9] |
| ALT (U/L) | 16 (13–21) [4] | 17 (14–44) [6] | 28 (21–28) [3] | 16 (14–28) [13] |
| D–Dimer ( | 0.54 (0.42–0.83) [4] | 0.66 (0.55–1.42) [7] | 0.94 (0.59–1.17) [3] | 0.63 (0.50–1.29) [14] |
| Ferritin (ng/mL) | 60.8 (51.2–99.7) [5] | 343.0 (162.5–540.6) [8] | 184.6 (NA) [2] | 179.1 (59.0–354.2) [15] |
| CRP (mg/dL) | 0.605 (0.420–1.190) [4] | 1.070 (0.900–2.565) [7] | 6.765 (NA) [2] | 1.03 (0.71–2.63) [13] |
|
| ||||
| Supplemental oxygen required | — | 4 (50) | 4 (80) | 8 (42) |
| Death | — | — | 1 (20) | 1 (5) |
| Length of hospital stay, days, median (IQR) | 6 (1–6) | 9 (7–10) | 10 (5–13) | 6 (5–10) |
Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; CRP = C-reactive protein; FEU = fibrinogen equivalent units; IQR = interquartile range (1st–3rd); NA = not applicable; WBC = white blood cell.
* Patients were classified as symptomatic if they had at least one listed symptom at the time of first positive specimen collection, presymptomatic if they did not exhibit symptoms at the time of specimen collection but later developed at least one listed symptom, and asymptomatic if they did not exhibit symptoms at any time between specimen collection and the last date of data collection.
† Asian, black, Native Hawaiian or Pacific Islander, and white residents in this cohort were non-Hispanic; Hispanic persons could be of any race.
§ Comorbidities were determined based on documented SNOMED CT and International Classification of Diseases, Ninth Revision codes and review of patient’s vital signs, laboratory values, imaging findings, and provider notes. Chronic kidney disease stage was calculated using the Cockcroft-Gault equation to determine creatinine clearance; patients with estimated glomerular filtration rates <30 mL per minute were considered stage 4 and above. One symptomatic patient was dialysis-dependent. Cardiovascular disease includes coronary artery disease, peripheral artery disease, and previous cerebrovascular accident.
¶ Symptoms were collected through review of all provider notes from March 26 through April 20. Constitutional, respiratory, and digestive symptoms were counted if any one of the symptoms at the time of or after testing was present as a change from baseline. Fever includes measured temperature >100.4°F (>38°C) or fever reported by provider.
** These values include the first available laboratory results within 48 hours of admission for each patient.
†† Reference values are as follows: WBC = 4.5–11.0 x 1,000 per μL; lymphocytes = 600–4,800 x 1,000 per μL; % lymphocytes = 20%–40%; creatinine = 0.66–1.28 mg per dL; AST = 13–35 U per liter; ALT = 7–45 U per liter; d-Dimer = 0.00–0.42 μg per mL FEU; ferritin = 22–322 ng per mL; CRP = 0–0.744 mg per dL.